January 3, 2019 07:12 AM EST

Bristol-Myers inks a $74B deal to buy out Celgene, expects $15B a year from late-stage pipeline

In a stunning turn of events, Bristol-Myers Squibb $BMY has struck a deal to buy Celgene $CELG for $74 billion in cash and stock. And …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bris­tol-My­ers inks a $74B deal to buy out Cel­gene, ex­pects $15B a year from late-stage pipeline